Brought to you by 
Y-mAbs licenses exclusive immunotherapy rights from Memorial Sloan Kettering
27 Oct 2017
Executive Summary
Memorial Sloan Kettering Cancer Center granted Y-mAbs Therapeutics Inc. exclusive global rights to two clinical-stage fully humanized antibodies and non-exclusive access to the MULTI-TAG protein multimerazation platform.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Y-mAbs licenses exclusive immunotherapy rights from Memorial Sloan Kettering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice